Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 12.60 |
---|---|
High | 12.70 |
Low | 10.00 |
Bid | 10.60 |
Offer | 10.70 |
Previous close | 14.00 |
Average volume | 2.36m |
---|---|
Shares outstanding | 1.20bn |
Free float | 1.20bn |
P/E (TTM) | -- |
Market cap | 166.47m ILS |
EPS (TTM) | -0.1898 ILS |
Data delayed at least 20 minutes, as of Nov 21 2024 15:24 GMT.
More ▼
- BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.
- BioLineRx to Report Third Quarter 2024 Results on November 25, 2024
- BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024
- BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide
- BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection
More ▼